The White House on Tuesday denied that President Donald Trump applied for access to an experimental obesity drug not yet on the market after Stat News reported that a 79-year-old man was approved to take it.

The health and science news outlet Stat News reported that the Food and Drug Administration and drug manufacturer Eli Lilly allowed one person — a 79-year-old man — special access to the drug retatrutide through a “compassionate use” program, citing three sources familiar with the matter. Those sources, Stat News reported, requested anonymity due to fear of reprisals.

According to the FDA, compassionate use is a “pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.”

The three sources familiar with the matter told Stat News that the person’s application for the drug caught the eye of top health officials, “suggesting the person receiving this drug was well connected.”

Stat News said it did not know the person’s identity, but the outlet asked the White House whether Trump had made the request, “given the patient demographics and the unusual nature of the application.” The report noted that Trump turned 80 earlier this month, is overweight and “ has expressed interest in obesity drugs.”

The White House directed Stat News to the Department of Health and Human Services. An HHS spokesperson did not address the retatrutide application or the patient’s identity, the outlet reported.

But on Tuesday, hours after the Stat News report was published, White House spokesman Kush Desai said on X that the “application was not for the President.” He went on to publicly bash the report’s author, Lizzy Lawrence, accusing her of being an “unserious gossip columnist.”

Lawrence responded on X that she had asked Desai, the FDA and HHS “multiple times” on Monday whether the application was for Trump. “No one answered my question directly,” she wrote. Desai called the report “baseless speculation” in a follow-up post.

Lilly spokesperson Misty Fuller told Stat News that the company does not comment on the specifics of individual compassionate use applications.

The safety and efficacy of retatrutide are still being studied in ongoing clinical trials for obesity, Type 2 diabetes and moderate to severe obstructive sleep apnea, among other conditions, according to Lilly.

National Institutes of Health Senior Clinician Ranganath Muniyappa requested the drug to treat the patient, who suffered from refractory obesity with obstructive sleep apnea and pulmonary hypertension, Stat News reported. Muniyappa, who did not respond to the outlet’s request for comment, reportedly recommended against bariatric surgery because of the patient’s age and medical conditions.

The patient also took tirzepatide, an FDA-approved obesity drug by Lilly, for one year, “but experienced only moderate weight loss,” Stat News reported, citing sources familiar with the matter.

Trump has had multiple medical physicals since returning to office last year. After his medical evaluation in May — his third in 13 months — the White House said the president “remains in excellent health” but was advised to lose weight and exercise more.

The post White House denies Trump applied for ‘compassionate use’ for weight loss drug appeared first on MS NOW.

Author: Source Author

From MS Now.